Kennametal (KMT) Tops Q1 EPS by 11c ; Offers Guidance

Kennametal (NYSE: KMT) reported Q1 EPS of $0.34, $0.11 better than the analyst estimate of $0.23. Revenue for the quarter came in at $498 million versus the consensus estimate of $477.68 million.

GUIDANCE:

Kennametal sees Q2 2026 EPS of $0.30-$0.40, versus the consensus of $0.23. Kennametal sees Q2 2026 revenue of $500-520 million, versus the consensus of $486.4 million.

Kennametal sees FY2026 EPS of $1.35-$1.65, versus the consensus of $1.09. Kennametal sees FY2026 revenue of $2.1-2.17 billion, versus the consensus of $1.99 billion.

For earnings history and earnings-related data on Kennametal (KMT) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c